This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

29 Jun 2012

COPD Drugs Market Geared for Change

ISR's latest report looks at the changes afoot in the COPD drugs market.

Significant changes are likely to take place in the market for chronic obstructive pulmonary disease (COPD) drugs over the next few years, a new report has claimed.


COPD is an umbrella term for a number of chronic lung diseases, including chronic bronchitis and emphysema.


There are approximately 64 million people in the world with COPD and the diseases included within the COPD diagnosis are expected to become the third leading cause of death by 2030, according to the World Health Organisation.


In its latest report, research firm Industry Standard Research (ISR) claims that the COPD market is likely to approach a value of $10 billion by 2017.


Related News